deltatrials
Completed PHASE3 NCT00051623

A Study of the Safety and Effectiveness of Infliximab for the Treatment of Psoriatic Arthritis

A Multicenter, Randomized, Double-blind Trial of Anti-TNFa Chimeric Monoclonal Antibody (Infliximab) for the Treatment of Patients With Psoriatic Arthritis

Sponsor: Centocor, Inc.

Conditions Arthritis, Psoriatic
Interventions Infliximab
Updated 5 times since 2017 Last updated: May 16, 2011 Started: May 31, 2003 Completion: Jun 30, 2004

Listed as NCT00051623, this PHASE3 trial focuses on Arthritis, Psoriatic and remains completed. Sponsored by Centocor, Inc., it has been updated 5 times since 2003, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

May 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Centocor, Inc.
Data source: Centocor, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.